Pharmaceutical

Leading Sales and Marketing Intent Data, Database and D...

Discover leading Sales & Marketing Intent Data Solutions for the Pharmaceutical ...

FDA approves Amgen’s combo therapy for colorectal cancer

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA ...

Novo Nordisk’s Ozempic named in latest Medicare price n...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbu...

Pfizer believes in the metaverse: will healthcare thaw ...

The metaverse hype is over, but developer Cassette Group has been working with P...

HEOR explained: Improving healthcare decisions with rea...

How longitudinal, closed claims data is advancing regulatory, epidemiology, and ...

Mega M&A at JP Morgan Conference 2025 — is biopharma M&...

Potential antitrust deregulation could foster a more favourable environment for ...

Charles River and Akron link to integrate cytokines int...

Charles River and Akron Bio have announced the integration of the latter’s CSS l...

FDA beats EMA to most approved new drugs in 2024

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most appr...

COPD market to expand with AstraZeneca’s focus on biolo...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to so...

JPM 2025: Lonza shares outlook on CHI exit and acquisit...

The Lonza CEO said the company is not under any pressure to exit the Capsules an...

Shionogi awarded $375m from HHS for preventative Covid-...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug...

IMPACT ovarian cancer capsules authorised in China

IMPACT Therapeutics has received the China NMPA marketing authorisation for Sena...

AbbVie and Simcere Zaiming link to develop trispecific ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the...

JP Morgan 2025: Incyte expects period of ‘defining cata...

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning wi...

Regenxbio and Nippon Shinyaku forge $810m gene therapy ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get...